Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment
AIM: The mineralocorticoid receptor (MR; also known as NR3C2) plays important roles in the modulation of blood pressure. The effect of NR3C2 polymorphisms on antihypertensive response to enalapril was investigated.
PATIENTS & METHODS: Two hundred and seventy nine essential hypertension patients treated with enalapril were genotyped for two NR3C2 tagSNPs, rs5522 and rs2070950, by Sequenom MassArray™ technology.
RESULTS: The reductions in diastolic blood pressure (DBP) were significantly greater in AA homozygotes compared with AG+GG genotype carriers for the rs5522 polymorphism (p = 0.009), and the reductions in DBP were greater in GG homozygotes compared with GC+CC genotype carriers for the rs2070950 polymorphism, with marginal significance (p = 0.065). Stepwise multiple regression analysis indicated that significant predictors of DBP reduction were baseline DBP (p < 0.001), waist:hip ratio (p = 0.001) and rs5522 genotype (p = 0.003).
CONCLUSION: NR3C2 rs5522 affects blood pressure response to enalapril treatment and may serve as a useful pharmacogenomic marker of antihypertensive response to enalapril in essential hypertension patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 15(2014), 2 vom: 03. Feb., Seite 201-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Luo, Jian-Quan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
69PN84IO1A |
|---|
| Anmerkungen: |
Date Completed 12.02.2015 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs.13.173 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM231095007 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM231095007 | ||
| 003 | DE-627 | ||
| 005 | 20231224085930.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs.13.173 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0770.xml |
| 035 | |a (DE-627)NLM231095007 | ||
| 035 | |a (NLM)24059494 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Luo, Jian-Quan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.02.2015 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: The mineralocorticoid receptor (MR; also known as NR3C2) plays important roles in the modulation of blood pressure. The effect of NR3C2 polymorphisms on antihypertensive response to enalapril was investigated | ||
| 520 | |a PATIENTS & METHODS: Two hundred and seventy nine essential hypertension patients treated with enalapril were genotyped for two NR3C2 tagSNPs, rs5522 and rs2070950, by Sequenom MassArray™ technology | ||
| 520 | |a RESULTS: The reductions in diastolic blood pressure (DBP) were significantly greater in AA homozygotes compared with AG+GG genotype carriers for the rs5522 polymorphism (p = 0.009), and the reductions in DBP were greater in GG homozygotes compared with GC+CC genotype carriers for the rs2070950 polymorphism, with marginal significance (p = 0.065). Stepwise multiple regression analysis indicated that significant predictors of DBP reduction were baseline DBP (p < 0.001), waist:hip ratio (p = 0.001) and rs5522 genotype (p = 0.003) | ||
| 520 | |a CONCLUSION: NR3C2 rs5522 affects blood pressure response to enalapril treatment and may serve as a useful pharmacogenomic marker of antihypertensive response to enalapril in essential hypertension patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a NR3C2 protein, human |2 NLM | |
| 650 | 7 | |a Receptors, Mineralocorticoid |2 NLM | |
| 650 | 7 | |a Enalapril |2 NLM | |
| 650 | 7 | |a 69PN84IO1A |2 NLM | |
| 700 | 1 | |a Wang, Lu-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a He, Fa-Zhong |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Ning-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Gen-Fu |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Jia-Gen |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Zhi-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhao-Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Hong-Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiao-Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 15(2014), 2 vom: 03. Feb., Seite 201-8 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2014 |g number:2 |g day:03 |g month:02 |g pages:201-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs.13.173 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2014 |e 2 |b 03 |c 02 |h 201-8 | ||